Metz, M.; Schuetz, A.; Weller, K. et al.
Omalizumab is effective and safe in symptomatic dermographism: results of UFO, a multicentre randomized, placebo-controlled trialALLERGY. Bd. 71. 2016 S. 185-185
Maurer, M.; Schutz, A.; Weller, K. et al.
Omalizumab is effective and well tolerated in cold urticaria: results of CUTEX, a multicentre randomized placebo-controlled trialALLERGY. Bd. 71. 2016 S. 39-39
Metz, M.; Torene, R.; Letzkus, M. et al.
Omalizumab normalizes gene expression in lesional skin of patients with chronic idiopathic/spontaneous urticaria: results from a randomized, double-blind, placebo-controlled studyEXPERIMENTAL DERMATOLOGY. Bd. 25. 2016 S. 19-19
Hassel, J.; Forschner, A.; Bluhm, L. et al.
Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP)JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. Bd. 14. 2016 S. 9-9
Ascierto, P. A.; Del Vecchio, M.; Robert, C. et al.
Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)ANNALS OF ONCOLOGY. Bd. 27. 2016
Herzberger, Jana; Fischer, Karl; Leibig, Daniel et al.
Oxidation-Responsive and "Clickable" Poly(ethylene glycol) via Copolymerization of 2-(Methylthio)ethyl Glycidyl EtherJOURNAL OF THE AMERICAN CHEMICAL SOCIETY. Bd. 138. H. 29. 2016 S. 9212-9223
Dietze-Schwonberg, Kirsten; Lorenz, Beate; Kostka, Susanna Lopez et al.
Parasite Clearance in Leishmaniasis in Resistant Animals Is Independent of the IL-23/IL-17A AxisJOURNAL OF INVESTIGATIVE DERMATOLOGY. Bd. 136. H. 9. 2016 S. 1906-1908
Waisman, Ari; Hoevelmeyer, Nadine; Diefenbach, Andreas et al.
Past, present and future of immunology in MainzCELLULAR IMMUNOLOGY. Bd. 308. 2016 S. 1-6
Schmidt, T.; Lorenz, N.; Raker, V. K. et al.
Pathogen recognition receptor-mediated immune processes in low zone tolerance to allergensEXPERIMENTAL DERMATOLOGY. Bd. 25. H. 3. 2016 S. E2-E2
Lebbe, C.; Dutriaux, C.; Lesimple, T. et al.
Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossoverANNALS OF ONCOLOGY. Bd. 27. 2016